Elevating Health Equity in Clinical Trials as a CRO

In Conversation with Daniel Perez

The importance of diverse representation in clinical trials cannot be overstated. It is crucial to ensure that medical advancements benefit all populations equally. Both pharmaceutical companies and Clinical Research Organizations (CROs) bear the responsibility of promoting health equity and play a critical role in achieving this goal.

Turning the Health Equity Spotlight

To gain a deeper understanding of the current state of clinical trials and ongoing advancements as it relates to health equity, Ryan Brown at H1 interviewed Daniel Perez, Global Head of Health Equity Strategy at Worldwide Clinical Trials.

daniel perez and ryan brown headshots

Perez, a trailblazer in health equity and diversity, brings his wealth of experience and insights to the forefront. He advocates for innovative approaches to ensure inclusivity and representation in clinical trial populations.

The interview covers:

  • Why health equity is important when thinking about a CRO versus a pharma company
  • Whether technology plays a role in promoting health equity
  • What impact H1 has on helping life sciences companies improve health equity

Watch the interview:

Technology to Transform Health Equity

H1’s Trial Landscape redefines efficiency for CROs and pharma companies in promoting diversity in clinical trials through the identification of diverse investigators, patient groups, and top trial sites, enhancing trial diversity and health equity. Request a demo to learn more.